Please select a Capability in order to start your service request.
BD Rhapsody™ single cell analysis system launches for gene expression profiling, plans to expand for protein analysisSep 12, 2017
FRANKLIN LAKES, N.J., Sept. 12, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of BD Rhapsody, a platform for single cell analysis with the ability to detect rare molecules responsible for biological diversity that are often missed with whole transcriptome profiling.
Developed using the company’s patented unique molecular index (UMI) technology, BD Rhapsody is a complete system of reagents, instruments and software for targeted gene expression analysis of tens of thousands of individual cells. The product was previously in limited commercial release under the name Resolve. BD will offer both application-specific targeted panels and enable customers to design their own custom, targeted panels.
“Early access users have been enthusiastic about our targeted assay solution and its superior performance compared to whole transcriptome profiling,” said Stephen Gunstream, vice president of Genomics for BD. “These same users have also experienced considerable sequencing cost savings from this technology.”
The BD Rhapsody platform assay offering will be rapidly expanded over the next 12 months. Shortly after launch, customers will be able to multiplex many samples in one run with the BD single-cell multiplexing kit, significantly increasing sample throughput while maintaining the low doublet rate. The platform is also being expanded beyond RNA expression to include protein detection, leveraging BD’s extensive antibody portfolio with BD AbSeq assays for protein expression.
“Initial data generated looks extremely positive and we believe true understanding of complex diseases will come with the ability to interrogate both protein and RNA in single cells simultaneously,” Gunstream added.
BD has initiated early access for AbSeq protein detection on the BD Rhapsody system and expects commercial availability in the first half of 2018. The BD Rhapsody system and AbSeq assays will be showcased at this year’s AGBT Precision Health and ASHG conferences.
These new products build on BD’s 40-year history of providing solutions for single cells using flow cytometry. With the BD Rhapsody system, researchers are able to easily discover both the gene expression and protein markers that more completely identify their cell population of interest.
Join BD at the AGBT meeting on Friday, Sept. 15 from 6:30 to 8:30 p.m. or on Saturday, Sept. 16 from 12:45 to 1 p.m. in the Camelback Ballroom for the workshop, BD Rhapsody system and AbSeq: Simultaneous RNA and protein analysis on tens of thousands of single cells.
More information on the BD Rhapsody system and the new BD single-cell multiplexing assays is available at bd.com/Rhapsody.
The BD Rhapsody system is for research use only and not for diagnostic or therapeutic use. For more information, contact BD at +1 650.665.2400.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.